ARDX Ardelyx
- 6.6992
- +0.0892+1.35%
Ardelyx News
Ardelyx(ARDX.US) Officer Sells US$192.06K in Common Stock
$Ardelyx(ARDX.US)$ Officer RAAB MICHAEL sold 30,000 shares of common stock on Apr 29, 2024 at an average price of $6.4019 for a total value of $192.06K.Source: Announcement What is statement of change
Express News | Ardelyx To Present Additional Data For XPHOZAH For Adults With Chronic Kidney Disease On Dialysis At National Kidney Foundation 2024 Spring Clinical Meetings
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH (Tenapanor) for Adults With Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings
WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class me
Form 144 | Ardelyx(ARDX.US) Officer Proposes to Sell 192.05K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 29, $Ardelyx(ARDX.US)$ Officer MICHAEL G. RAAB intends to sell 30,000 shares of its common stock on Apr 29, with a total market value of approximately $192.05K. MICHAEL G
Ardelyx's (NASDAQ:ARDX) Investors Will Be Pleased With Their Favorable 91% Return Over the Last Five Years
Piper Sandler Sticks to Its Buy Rating for Ardelyx (ARDX)
Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024
Conference call scheduled for 4:30 p.m. Eastern TimeWALTHAM, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, d
Ardelyx(ARDX.US) Officer Sells US$52,923.75 in Common Stock
$Ardelyx(ARDX.US)$ Officer RAAB MICHAEL sold 7,500 shares of common stock on Apr 15, 2024 at an average price of $7.0565 for a total value of $52,923.75.Source: Announcement What is statement of chang
Ardelyx Is Maintained at Outperform by Wedbush
Ardelyx Is Maintained at Outperform by Wedbush
Express News | Wedbush Maintains Outperform on Ardelyx, Raises Price Target to $14
Insiders At Ardelyx Sold US$1.1m In Stock, Alluding To Potential Weakness
Ardelyx, Inc. (NASDAQ:ARDX) shareholders may have reason to be concerned, as several insiders sold their shares over the past year. When analyzing insider transactions, it is usually more valuable t
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Byrna Technologies Inc. (NASDAQ:BYRN) rose sharply during Friday's session after the company reported better-than-expected first-quarter revenue, and announced a CFO transition. Byrna Techno
Express News | Ardelyx Shares Are Trading Higher After Leerink Partners Initiated Coverage on the Stock With an Outperform Rating and $14 Price Target
Ardelyx Initiated at Outperform by Leerink Partners
Ardelyx Initiated at Outperform by Leerink Partners
A Closer Look at 6 Analyst Recommendations For Ardelyx
Analysts' ratings for Ardelyx (NASDAQ:ARDX) over the last quarter vary from bullish to bearish, as provided by 6 analysts.The table below provides a snapshot of their recent ratings, showcasing how se
Express News | Leerink Partners Initiates Coverage On Ardelyx With Outperform Rating, Announces Price Target of $14
Ardelyx Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/05/2024 91.78% Leerink Partners → $14 Initiates Coverage On → Outperform 02/23/2024 105.48% Piper Sandl
Ardelyx(ARDX.US) Officer Sells US$11,096.58 in Common Stock
$Ardelyx(ARDX.US)$ Officer RAAB MICHAEL sold 1,518 shares of Common Stock on Apr 1, 2024 at an average price of $7.31 for a total value of $11,096.58.Source: Announcement What is statement of changes
Ardelyx: Kelliher Served as Group Vice Pres, M&A and Business Development, at Horizon Therapeutics >ARDX
Ardelyx: Kelliher Served as Group Vice Pres, M&A and Business Development, at Horizon Therapeutics >ARDX
Ardelyx Appoints Mike Kelliher, as Executive Vice Pres, Corporate Development and Strategy
Ardelyx Appoints Mike Kelliher, as Executive Vice Pres, Corporate Development and Strategy
Analysis
Price Target
No Data
